System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Youlia Kirova is an expert in Radiotherapy at Institut Curie (France). As of October 2026, ScienceLeadR ranks Youlia Kirova in the top 1% of experts worldwide for Breast Diseases, Breast Neoplasms and Cardiotoxicity. Youlia Kirova has authored 742 publications, the most recent in 2026, and is an investigator in 12 clinical trials, 1 of them ongoing. SLR score: 2,723 (community average: 125). How the SLR is computed.

LeadR Profile

Youlia Kirova Institut Curie France
2 723 ScienceLeadR Reputation 2723

Unlock

Register Login
Network Map

Radiotherapy

Subspecialties: Oncology - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1997 - 2026
Source: PubMed

Institut Curie

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 742

Citations

Citations: 10 071 1st author: 79 Last author: 316 Unique author: 7

Main journals

Cancer Radiother 146
Radiother Oncol 94
Int J Radiat Oncol Biol Phys 88
Cancer Res 56
Cancers (Basel) 20

Best Journals

Ann Oncol 4
J Clin Oncol 4
Lancet Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Neoadjuvant Chemotherapy Increases Genomic Radioresistance in Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Implications for Radiation Sensitivity Index/Genomic-Adjusted Radiation Dose-Guided Radiation Therapy Personalization.
PMID 42936472 — radiotherapy, genes, radiation tolerance, epidermal growth factor, growth, breast neoplasms, neoplasms, drug therapy, hormones, receptors, growth factor, breast, therapeutics, chemotherapy		Adv Radiat Oncol20260
Update on radiotherapy for breast cancer at the SFRO annual congress 2026.
PMID 42933258 — radiotherapy, breast neoplasms, neoplasms, breast		Cancer Radiother20260
ESTRO consensus recommendations on total skin electron beam technique - Endorsed by ILROG.
PMID 42830810 — radiotherapy, skin, lymphoma, therapeutics		Phys Imaging Radiat Oncol20260
Second Breast-Conserving Treatment for Ipsilateral Breast Tumor Recurrence: A Review of Patient Selection, Reirradiation Techniques, and Clinical Outcomes.
PMID 42638516 — radiotherapy, mastectomy, breast neoplasms, brachytherapy, neoplasms, re-irradiation, breast, therapeutics		Int J Cancer20260
The place of radiotherapy in the treatment of inflammatory breast cancer: Practical questions and responses.
PMID 42566857 — radiotherapy, breast neoplasms, neoplasms, inflammatory breast neoplasms, breast, therapeutics		Cancer Radiother20260

Clinical Studies 12

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3 Study Director: 1

By phase:

N/A 5
Phase 3 3
Phase 1 2
Phase 2 2

By status:

Completed 6
Recruiting 2
Unknown 2
Active not recruiting 1
Terminated 1

By type:

Interventional 9
Observational 3

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 2
multicentric5to9 2
multicentricup10 1

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Atrial Fibrillation and Other Cardiac Arrhythmias and Diseases After Radiotherapy for Breast Cancer Watch Your HeaRT
NCT06073509 — radiotherapy, heart diseases, breast neoplasms, heart, arrhythmias, cardiac, data collection, neoplasms, pathology, atrial fibrillation, breast, echocardiography, cardiomyopathies, electrocardiography		N/ARecruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS